Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Monday, June 10, 2024
Efforts to identify effective therapeutic strategies for patients with previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC) have revealed the clinical benefits associated with adagrasib therapy, according to the results of the KRYSTAL-12 study, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract LBA8509). Treatment with the KRAS G12C inhibitor significantly improved clinical outcomes compared with the standard-of-care docetaxel in this patient population, explained Tony S.K. Mok, MD, FRCPC, FASCO, of The Chinese University of Hong Kong, China, and colleagues.
A total of 453 patients with KRAS G12C–mutated locally advanced or metastatic NSCLC were recruited for the study. All patients had a history of treatment with platinum-based chemotherapy and anti–PD-L1 therapy. Patients were randomly assigned to receive treatment with either adagrasib (n = 301) or docetaxel (n = 152). Those treated with docetaxel could cross over to receive treatment with adagrasib if they had evidence of disease progression.
The study authors reported a significantly improved median progression-free survival in patients treated with adagrasib (5.5 months) compared with patients treated with docetaxel (3.8 months, hazard ratio = 0.58). Similarly, the objective response rate was significantly elevated for patients treated with adagrasib (31.9%) compared with patients treated with docetaxel (9.2%, odds ratio = 4.68). In addition, the median durations of response were 8.3 months and 5.4 months for patients treated with adagrasib and docetaxel, respectively. Moreover, treatment-related adverse events were experienced by 94.0% of patients treated with adagrasib and 86.4% of patients treated with docetaxel.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
JNCCN Spotlights
